Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24 Novembre 2023 - 1:00PM
Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023,
the Compensation Committee of Chimerix’s Board of Directors granted
an inducement award to a new employee of non-qualified stock
options to purchase 150,000 shares of Chimerix’s common stock. The
Compensation Committee of Chimerix’s Board of Directors approved
the award as an inducement material to the new employee’s
employment agreement in accordance with Nasdaq Listing rule
5635(c)(4).
The stock option has an exercise price per share equal to $1.00
per share, Chimerix’s closing trading price on November 20, 2023.
The stock option has a 10-year term and will vest over four years,
with one-fourth vesting on the one-year anniversary of the grant
date and the remaining three-fourths vesting over the following
three years in equal monthly installments. The stock option is
subject to the terms of Chimerix’s 2013 Equity Incentive Plan but
was granted outside of the 2013 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACTS:
Michelle LaSpaluto919 972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024